Navigation Links
BZL101 in Medical News

Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Announces Presentation at the National Cancer Institute

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces Cost Control Measures Taken

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces 2007 Financial Results and Highlights

...er Research (AACR). The presentation described how bzl101 elicits its cytotoxic activity on cancer cel... patients into a Phase 1/2 clinical trial of bzl101 for the treatment of advanced breast cancer, after presenting positive Phase 1 findings of bzl101 at the American Association of Cancer Resear...
BZL101 in Medical Technology

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...

Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles

- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...

Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101

BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...

Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial

...es of its innovative breast cancer drug candidate, bzl101 were well tolerated. As a result, the company will... available efficacy information." About BZL101 bzl101 is an oral drug designed for the treatment of adva...argely on glycolysis (>85%) for energy production. bzl101 leads to energy collapse in cancer cells by inhibi...

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research

... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...

Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial

...men's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancrea...
BZL101 in Biological Technology

Bionovo Announces 2008 Highlights and Year-End Financial Results

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Reports Third Quarter 2008 Financial Results

... of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included: -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer has now been completed successfully, showing positive safety and tolerabil...

Bionovo Reports Second Quarter 2008 Financial Results

...rence of $4.6 million. Company Highlights -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues su...al trials for both MF101 and VG101." "We are very excited at the progress bzl101 is making in the clinical trials for advanced breast cancer. This drug cand...

Bionovo Reports First Quarter 2008 Financial Results

...th $33.3 million, a difference of $3.9 million. Company Highlights -- Patient enrollment and dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. Presentations, papers and scientific discussions have expounded the mechanis...

Bionovo Announces Third Quarter 2007 Financial Results

...dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. -- Bionovo presented data on bzl101 at the AACR-NCI-EORTC International Conference...r Targets and Cancer Therapeutics showing that bzl101 selectively elicits its cytotoxic activity on canc...
Other Tags
(Date:12/20/2014)... -- The holidays can be anything but joyous for ... scented candles and other allergy triggers. "The dust ... been packed away in dank basements or dusty attics ... Dr. Rachna Shah, an affiliate faculty member at Loyola ... news release. Shah, who is also an allergist ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... 20, 2014 The Twin Cities DI ... event in the nation! Over 250 financial professionals come ... information on the industry, get motivated to protect their ... people facing and overcoming the challenges of disability. , ... the nation came together to attend The 13th Annual ...
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
Other Contents